Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine for Type 2 Diabetes prevention in obese adolescents
NCT02351323Phase 1Completed
- Sponsor
- Boston Medical Center
- Start
- May 2010
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glutamine in type 2 diabetes mellitus (T2DM), sponsored by Boston Medical Center. Primary endpoint: Weight gain at 14 weeks. Started May 2010; status: completed.
02
Drugs
glutamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02351323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351323.